nilutamide has been researched along with Prostatic Hyperplasia in 3 studies
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chauhan, G | 1 |
| Mehta, A | 1 |
| Gupta, S | 1 |
| Benassayag, E | 1 |
| Namer, M | 1 |
1 review available for nilutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
1 trial available for nilutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Indications of antiandrogens in benign hyperplasia of the prostate].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Imidazoles; I | 1995 |
1 other study available for nilutamide and Prostatic Hyperplasia
| Article | Year |
|---|---|
Stromal-AR influences the growth of epithelial cells in the development of benign prostate hyperplasia.
Topics: Androgen Antagonists; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Epithelial Ce | 2020 |